DE69928100D1 - Modulatoren der protein tyrosin phosphatase (ptpases) - Google Patents
Modulatoren der protein tyrosin phosphatase (ptpases)Info
- Publication number
- DE69928100D1 DE69928100D1 DE69928100T DE69928100T DE69928100D1 DE 69928100 D1 DE69928100 D1 DE 69928100D1 DE 69928100 T DE69928100 T DE 69928100T DE 69928100 T DE69928100 T DE 69928100T DE 69928100 D1 DE69928100 D1 DE 69928100D1
- Authority
- DE
- Germany
- Prior art keywords
- diseases
- compounds
- ptpases
- protein tyrosine
- shp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title abstract 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 abstract 1
- 108091006442 Mitochondrial phosphate transporters Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrodes Of Semiconductors (AREA)
- Enzymes And Modification Thereof (AREA)
- Bipolar Transistors (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Control Of El Displays (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK34498 | 1998-03-12 | ||
| DK48098 | 1998-04-03 | ||
| DKPA199800938 | 1998-07-15 | ||
| DKPA199801385 | 1998-10-28 | ||
| DKPA199801612 | 1998-12-07 | ||
| PCT/DK1999/000121 WO1999046267A1 (en) | 1998-03-12 | 1999-03-11 | Modulators of protein tyrosine phosphatases (ptpases) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69928100D1 true DE69928100D1 (de) | 2005-12-08 |
Family
ID=27512769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69928100T Expired - Lifetime DE69928100D1 (de) | 1998-03-12 | 1999-03-11 | Modulatoren der protein tyrosin phosphatase (ptpases) |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1080095B1 (https=) |
| JP (1) | JP2002506072A (https=) |
| KR (1) | KR20010041814A (https=) |
| CN (1) | CN1300291A (https=) |
| AT (1) | ATE308546T1 (https=) |
| AU (1) | AU2713599A (https=) |
| BR (1) | BR9908726A (https=) |
| CA (1) | CA2323493A1 (https=) |
| DE (1) | DE69928100D1 (https=) |
| HU (1) | HUP0104984A3 (https=) |
| IL (1) | IL138319A0 (https=) |
| NO (1) | NO20004527L (https=) |
| PL (1) | PL342816A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4224566B2 (ja) | 2000-12-18 | 2009-02-18 | 株式会社医薬分子設計研究所 | 炎症性サイトカイン産生遊離抑制剤 |
| CN101103977A (zh) * | 2002-06-05 | 2008-01-16 | 株式会社医药分子设计研究所 | 糖尿病治疗药 |
| EP1512396A4 (en) * | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT |
| EA009701B1 (ru) | 2002-06-06 | 2008-02-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Противоаллергические средства |
| CA2488363C (en) | 2002-06-06 | 2011-01-04 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
| DK1753512T3 (da) * | 2004-05-28 | 2008-11-17 | 4Sc Ag | Tetrahydropyridothiophener |
| CA2568718A1 (en) * | 2004-06-04 | 2005-12-15 | Altana Pharma Ag | Tetrahydropyridothiophenes for use in the treatment of cancer |
| CA2569623A1 (en) * | 2004-06-11 | 2005-12-22 | Altana Pharma Ag | Novel compounds and use of tetrahydropyridothiophenes |
| LT2502911T (lt) * | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| AU2006212224A1 (en) * | 2005-02-09 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| AU2006212179A1 (en) * | 2005-02-11 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| WO2007031428A1 (en) * | 2005-09-15 | 2007-03-22 | F. Hoffmann-La Roche Ag | 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| SG10201510665WA (en) * | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| CN102382076B (zh) * | 2010-09-03 | 2016-08-17 | 中国医学科学院药物研究所 | 芳酮和芳酰胺类化合物及其制法和药物用途 |
| CN102838625B (zh) * | 2011-06-22 | 2015-04-15 | 中国科学院上海药物研究所 | 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途 |
| EP2948147B1 (en) * | 2013-01-28 | 2019-03-13 | H. Lundbeck A/S | N-substituted-5-substituted phthalamic acids as sortilin inhibitors |
| CN106748999A (zh) * | 2015-03-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
| CN104788425A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途 |
| CN104725308A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104829629B (zh) * | 2015-03-26 | 2017-03-15 | 天津药物研究院有限公司 | 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途 |
| MA45795A (fr) | 2016-07-29 | 2019-06-05 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| PT3494119T (pt) | 2016-07-29 | 2024-12-10 | Pgi Drug Discovery Llc | Compostos e composições e seus usos |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| CA3070993C (en) | 2017-08-02 | 2025-05-20 | Sunovion Pharmaceuticals Inc. | ISOCHROMANE COMPOUNDS AND THEIR USES |
| UA130249C2 (uk) | 2018-02-16 | 2025-12-31 | Сумітомо Фарма Америка, Інк. | Солі, кристалічні форми і способи їх отримання |
| EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
| WO2020233645A1 (zh) | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| US11629130B2 (en) * | 2020-04-14 | 2023-04-18 | Purdue Research Foundation | Lymphoid-specific tyrosine phosphatase (LYP) inhibitors |
| CA3180115A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
-
1999
- 1999-03-11 CA CA002323493A patent/CA2323493A1/en not_active Abandoned
- 1999-03-11 HU HU0104984A patent/HUP0104984A3/hu unknown
- 1999-03-11 EP EP99907332A patent/EP1080095B1/en not_active Expired - Lifetime
- 1999-03-11 DE DE69928100T patent/DE69928100D1/de not_active Expired - Lifetime
- 1999-03-11 BR BR9908726-0A patent/BR9908726A/pt not_active IP Right Cessation
- 1999-03-11 KR KR1020007010093A patent/KR20010041814A/ko not_active Withdrawn
- 1999-03-11 JP JP2000535645A patent/JP2002506072A/ja not_active Withdrawn
- 1999-03-11 IL IL13831999A patent/IL138319A0/xx unknown
- 1999-03-11 AT AT99907332T patent/ATE308546T1/de not_active IP Right Cessation
- 1999-03-11 PL PL99342816A patent/PL342816A1/xx not_active Application Discontinuation
- 1999-03-11 CN CN99806016A patent/CN1300291A/zh active Pending
- 1999-03-11 AU AU27135/99A patent/AU2713599A/en not_active Abandoned
-
2000
- 2000-09-11 NO NO20004527A patent/NO20004527L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002506072A (ja) | 2002-02-26 |
| IL138319A0 (en) | 2001-10-31 |
| PL342816A1 (en) | 2001-07-02 |
| BR9908726A (pt) | 2000-11-21 |
| EP1080095A1 (en) | 2001-03-07 |
| KR20010041814A (ko) | 2001-05-25 |
| HUP0104984A2 (hu) | 2002-04-29 |
| EP1080095B1 (en) | 2005-11-02 |
| CN1300291A (zh) | 2001-06-20 |
| HUP0104984A3 (en) | 2003-07-28 |
| NO20004527D0 (no) | 2000-09-11 |
| ATE308546T1 (de) | 2005-11-15 |
| CA2323493A1 (en) | 1999-09-16 |
| AU2713599A (en) | 1999-09-27 |
| NO20004527L (no) | 2000-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69928100D1 (de) | Modulatoren der protein tyrosin phosphatase (ptpases) | |
| DE60023923D1 (de) | Modulatoren der protein tyrosin phosphatase (ptpases) | |
| BR9911786A (pt) | Inibidores heterocìclicos de p38 | |
| DE60216952D1 (de) | Beta-carbolin-derivate als ptp-inhibitoren | |
| HUP0003351A2 (hu) | 2-Szubsztituált-4,5-diaril-imidazolok, eljárás e vegyületek előállítására, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| ATE329920T1 (de) | Modulatoren der protein tyrosin phosphatase (ptpases) | |
| ATE415164T1 (de) | (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung | |
| BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
| CY1109069T1 (el) | Ενωσεις ιμιδαζοπυριδαζινης | |
| ATE432072T1 (de) | Verwendung von adapalen zur behandlung dermatologischer erkrankungen | |
| ATE423769T1 (de) | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten | |
| DE69729125D1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
| EP1878725A3 (en) | Pyrimidine derivatives and their use as CB2 modulators | |
| MA27063A1 (fr) | Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation | |
| ATE475716T1 (de) | Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen | |
| BR9910458A (pt) | Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor | |
| ATE339968T1 (de) | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit | |
| BR9815596A (pt) | Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase | |
| DE60322186D1 (de) | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem | |
| BR9908215A (pt) | Derivados de ácidos hidroxâmico e carboxìlico | |
| BR0306838A (pt) | Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE69520430D1 (de) | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon | |
| MX2008011473A (es) | El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |